One-Step Hepatitis C Testing Now in BC!

HepCBC is celebrating One-Step Hep C Testing in BC! Those tested in BC will no longer have to await results of the screening (HCV antibody) test, then take a confirmatory (RNA) test, with several weeks from the first test to the final results. Congratulations, BCCDC and PHSA!! Besides enabling patients quicker access to lifesaving treatment, this will also save BC an estimated $1 million per year! http://www.phsa.ca/about/news-stories/stories/new-lab-proc

New Study Shows Potential Benefits of Screening All New Cancer Patients for Hepatitis

January 17, 2019, USA: “Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices" By Scott D. Ramsey, MD, PhD; Joseph M. Unger, PhD; Laurence H. Baker,DO; et al This study of 3051 patients attempted to determine the prevalence of chronic hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly-diagnosed cancer. It found 0.6% p...

Hologic Obtains Canadian Approval for Aptima® Hepatitis C and B Quant Assays

MARLBOROUGH, Mass., Nov. 10, 2016 /CNW/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that it has obtained approval from Health Canada for the Company's hepatitis C and B assays. The Aptima® HCV and HBV Quant assays are nucleic acid amplification tests for the quantitative detection of RNA from hepatitis C, and DNA from hepatitis B-infected patients.  These assays supplement the already available Aptima HIV-1 Quant assay, rounding out the Company's vir

UNITAID and FIND launch initiative to improve diagnostics and treatment for hepatitis C

GENEVA - UNITAID today announced a partnership with FIND to improve diagnostics and treatments for hepatitis C virus (HCV) and make them more affordable and widely available to those in need. The US $38.3 million project will support the development of better, simpler,  diagnostic tools for HCV where people seek care, and will introduce HCV testing and treatment over three and a half years in HIV programmes in seven countries: Cameroon, Georgia, India, Ma

APRI

AST to Platelet Ratio Index (APRI)   APRI above 1.5 can indicate advanced HCV liver damage. WARNING:  Do NOT use APRI alone as its accuracy rate is not sufficient to do so; experts recommend using a combination of two or  all three of the non-invasive liver tests (APRI, FibroSure/FibroTest, or FibroScan). Using the results of APRI, a non-invasive test, one can very roughly determine whether one has a high risk of having advanced live

Fibroscan

FibroScan Alternative to Biopsy   Echosens™ Machine FIBROSCAN (also known as transient elastography, a technology developed by Echosens™ of Paris, France) poses the greatest competition to biopsy as it is non-invasive, less expensive, and (arguably) equally accurate in measuring degree of liver inflammation and fibrosis, particularly in the higher end of the Metavir scale (Stages 3 and 4).   Below you will find a Co

Tests & Results

The most common tests A variety of different tests are used to diagnose hepatitis C. These include: • HCV Antibody Test - This test is usually the first test, and only tells you if you have been ever been exposed to HCV. Usually this is a BLOOD TEST but other methods sometimes used are a rapid saliva test (from a mouth swab), and a dried blood spot test (from a finger prick) • HCV Viral Load Test or HCV RNA Test - This is the second test which you tak